← Eichor
Study identifier: NCT05728996 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Netherlands Cohort Study on Acute HIV Infection

Condition: Acute HIV Infection  ·  Sponsor: Prof. Jan Prins

PhaseN/A
Planned participants183
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Investigation of the size, variability and localization of the (pro) viral reservoir and the properties of HIV-specific immune response related to "post-treatment viral remission' achievement and / or duration. In addition we will study the factors that determine latency in the different host cells, their sensitivity to induction of replication competent virus by various agents and the potential application of these agents in "post-treatment viral remission". This all will be studied in patients included during acute phase of the infection who start antiretroviral therapy immediately upon diagnosis.

This description comes directly from the study's public registry record.

Talk to the study team

Pien van Paassen, MD  ·  0031642970500  ·  p.vanpaassen@amsterdamumc.nl

Godelieve de Bree, MD PhD  ·  g.j.debree@amsterdamumc.nl

Always discuss trial participation with your own doctor first.

Locations (1)

Amsterdam UMC, location AMCAmsterdam, North Holland, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05728996